Coadministration of subcutaneous long-acting insulin reduced duration (68.5 vs 72 hours, p = 0.0001) and dose of insulin infusion (3.48 vs 4.04 units/kg, p = 0.016). It also decreased hypoglycemia events (12 vs 22, p = 0.029) without increasing hypokalemia risk (19 vs 12, p = 0.147). The gene discussed is INS; the disease is Hypokalemia.